# Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting

Study · id `cardio:ct-nct04898569` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04898569](<https://clinicaltrials.gov/study/NCT04898569>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04898569

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04898569. Randomized; single masking; primary purpose treatment. Start 2019-02-10 (actual); primary completion 2022-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04898569, source copy `cardio:ctgov-nct04898569-2021-05-24`, retrieved 2026-10-26)
- Started: 2019-02-10 (actual) (ClinicalTrials.gov record NCT04898569, source copy `cardio:ctgov-nct04898569-2021-05-24`, retrieved 2026-10-26)
- Primary completion: 2022-10-01 (anticipated) (ClinicalTrials.gov record NCT04898569, source copy `cardio:ctgov-nct04898569-2021-05-24`, retrieved 2026-10-26)
- Completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04898569, source copy `cardio:ctgov-nct04898569-2021-05-24`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04898569, source copy `cardio:ctgov-nct04898569-2021-05-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04898569-2021-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting
- Condition: Coronary Artery Disease
- Intervention (Drug): Ferinject
- Intervention (Drug): Normal Saline Flush
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: bf366135e766aef6344cabc60bdb1c5ab488fafe71e7d7179ff6e77dc8c77b5d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
